Abstract: Methods and compositions are provided for increasing muscle hypertrophy, e.g., through the administration of novel combinations of natural products that inhibit SIRT1.

Abstract: Methods and compositions are provided for increasing muscle hypertrophy, e.g., through the administration of novel combinations of natural products that inhibit SIRT1.

Abstract: Systems and methods are described providing therapeutic preparations of sirtuin inhibitors, such as SIRT1 inhibitors, for stimulating load-induced skeletal muscle growth in the body of a patient. The natural stimulation of SIRT1 activity can be suppressed through increased caloric intake and loading in conjunction with the inhibition of sirtuin activity to improve the inhibitory effect. In addition, known muscle growth promoting agents such as amino acids and hormones can be administered at the same time as the sirtuin inhibitor. The size of the tissue structure to be treated or the body size may be used to determine the therapeutic dose of sirtuin inhibitor. The sirtuin inhibitor and muscle stimulating agents are either locally or systemically delivered at therapeutic doses for the desired effect. The SIRT1 inhibitor Splitomycin is particularly effective.

Abstract: Systems and methods are described providing therapeutic preparations of sirtuin inhibitors, such as SIRT1 inhibitors, for stimulating load-induced skeletal muscle growth in the body of a patient. The natural stimulation of SIRT1 activity can be suppressed through increased caloric intake and loading in conjunction with the inhibition of sirtuin activity to improve the inhibitory effect. In addition, known muscle growth promoting agents such as amino acids and hormones can be administered at the same time as the sirtuin inhibitor. The size of the tissue structure to be treated or the body size may be used to determine the therapeutic dose of sirtuin inhibitor. The sirtuin inhibitor and muscle stimulating agents are either locally or systemically delivered at therapeutic doses for the desired effect. The SIRT1 inhibitor Splitomycin is particularly effective.

Abstract: This invention relates to a three dimensional bioengineered sphincter such as a bioengineered internal anal sphincter (IAS) and three-dimensional physiological models of smooth muscle cells. The invention also related to methods for generating a bioengineered sphincter and smooth muscle rings in culture. In addition, the invention provides for methods of using a bioengineered sphincter or bioengineered smooth muscle ring to identify agents that modify contractile force and relaxation in smooth muscle cells.

Abstract: This invention relates to a three dimensional bioengineered sphincter such as a bioengineered internal anal sphincter (IAS) and three-dimensional physiological models of smooth muscle cells. The invention also related to methods for generating a bioengineered sphincter and smooth muscle rings in culture. In addition, the invention provides for methods of using a bioengineered sphincter or bioengineered smooth muscle ring to identify agents that modify contractile force and relaxation in smooth muscle cells.